Cleveland Clinic spinoff receives $1.7 million commitment from Alzheimer’s Drug Discovery Foundation

Story excerpt provided by Crain’s Cleveland Business.

NeuroTherapia Inc., a Cleveland Clinic spinoff company, said it has received a $1.7 million commitment from the Alzheimer’s Drug Discovery Foundation to advance its NTRX-07 drug toward human clinical trials.

The therapy “targets a cannabinoid receptor in the brain, which is a new approach for treating Alzheimer’s and other neurologic diseases,” NeuroTherapia said in a news release.

Click here to read the complete article.

Originally published September 22, 2016.